Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by biorunon May 12, 2021 1:11pm
247 Views
Post# 33183575

Nda on Top 10

Nda on Top 10Does anyone know when the NDA would typically expire with this Top 10 company that co-funded the trial as they were interested in the 0.4% formulation? It seems like a reasonable time frame to make a decision has happened but I am not an expert on these matters.

Question for the pharma experts: if the NDA period is over, and the results of the 0.4% clinical trial are considered very good/material in nature (which based upon the previous news release indicated), would they be required to disclose these further details of the trial with shareholders or no?

If they had term sheets in their posession, will these also be relevant for release as well?

Keeping us all in the dark here is certainly not helpful for the share price, at least if they are working on some great items. If they want people to reinvest on the market, then new information or insight is needed, at least to make a semi-informed decision.

In the very least, we will have more information from the CEO in a week or two.
<< Previous
Bullboard Posts
Next >>